LeonaBio Q3 Cash Falls to $32.3M; Going Concern Warning Reiterated
LONA sits 46% above its 52-week low of $2.21 on light trading volume (0.3× avg).
Summary
LeonaBio ended Q3 with $32.3M in cash and investments and reiterated substantial doubt about its ability to continue as a going concern, after the 23.0M Series A warrants expired unexercised and its ATM remains blocked until December 2026.
Key Events · Earnings and Guidance · LONA
-
Going Concern Warning Reiterated
Management states that $32.3M of cash, cash equivalents and investments at September 30, 2026 will not fund operating expenses and capex for at least the next 12 months, raising substantial doubt about the ability to continue as a going concern.
-
Cash Burn Accelerates
Cash and investments fell to $32.3M from $88.3M at December 31, 2025; net cash used in operations was $56.8M for the nine months, and the net loss was $73.1M versus $22.7M a year earlier.
-
Series A Warrants Expire Worthless
The 23,031,494 Series A Common Warrants at a $6.35 strike became exercisable September 18, 2026 and expired unexercised on October 19, 2026, so they provided no capital.
-
ATM Blocked Until December 2026
The $75.0M Cantor Fitzgerald/BTIG at-the-market facility cannot be used because the company is ineligible to use Form S-3 through December 2026; no shares have been sold under it.
Analysis · LONA · Life Sciences
Management now says the $32.3M left at September will not fund operations for the next 12 months — a substantial-doubt going-concern conclusion — after $56.8M of operating cash burned in nine months. The safety valve investors were counting on is gone: the 23.0M Series A warrants at a $6.35 strike expired unexercised on October 19, 2026, so the roughly $146M they could have raised never materialized. With the $75.0M ATM unusable until Form S-3 eligibility returns in December 2026, the company must raise equity through a private placement or an S-1, and it explicitly flags possible discounted equity, tranched structures and additional warrants. Because the Phase 3 ELAINE-3 readout is not expected until the second half of 2027, the funding gap comes well before any data catalyst.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LONA was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4M. The 52-week trading range was $2.21 to $14.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.